Two Hyderabad-based researchers, Prof. Dr. Mamidanna Sreedhar and Dr. Mamidanna Varun, have submitted a design application to the Government of India for a smart wearable device aimed at monitoring chemotherapy side effects and predicting toxicity levels. The proposal aligns with growing interest in remote patient monitoring and oncology-focused digital health tools.
Wearable band designed for continuous, non-invasive monitoring
The device is conceived as an adjustable band worn on the wrist or arm, featuring a lightweight, ergonomic build for close skin contact and prolonged use. It comprises a central main module with a circular or oval housing that includes a display and linear button interface, encased for durability and easy handling. An elongated auxiliary module is integrated along the band, incorporating aligned indicator segments or sensor windows within a rectangular casing to expand sensing coverage.
The band uses a dual-layer structure, offering a smooth inner surface for comfort and a contoured outer layer for support. An adjustable fastening mechanism accommodates different users, while flexible structural links connect the main and auxiliary modules to maintain alignment without compromising movement.
Intended use in oncology care and remote health services
According to the application, the wearable is designed to help patients undergoing chemotherapy by tracking physiological responses and signalling early signs of toxicity. The system supports:
- Continuous or periodic monitoring of parameters linked to adverse reactions
- Early detection of toxicity trends to enable timely medical intervention
- User comfort to encourage consistent wear and adherence
- On-device visual feedback and basic controls for ease of use
- Integration with telemedicine platforms for remote data sharing
- Preventive care by flagging deviations before complications escalate
Multi-sensor architecture with predictive analysis
The proposed design integrates multiple sensors across the main and auxiliary modules to capture indicators such as skin temperature, galvanic skin response, and other chemotherapy-relevant biomarkers. Data acquired through onboard electronics is processed to identify abnormal patterns and deviations from baseline. Trend analysis underpins the prediction of potential toxicity levels, allowing clinicians to adjust treatment protocols proactively.
The auxiliary unit’s distributed sensing approach enhances accuracy by collecting signals from multiple points along the limb. Stable skin contact, enabled by the flexible band and contoured fit, is intended to reduce motion artefacts and improve data reliability. The display and indicator segments provide at-a-glance status and parameter readouts for users and caregivers.
Context: growing focus on patient-centric oncology devices
Wearable technologies are increasingly being explored in oncology to complement routine assessments with continuous, real-world data. Systems that can detect early warning signs—such as fever, dehydration risk, or autonomic changes—may help reduce emergency admissions and personalise chemotherapy dosing. The researchers’ application reflects this shift towards connected care, though regulatory review and clinical validation would be critical before any deployment.
